Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-?B expressions
| Autor: | Gökçe Ceren Kuşçu, Timur Köse, Nefise Ülkü Karabay Yavaşoğlu, Aylin Buhur, Melih Dağdeviren, Çevik Gürel, Altuğ Yavaşoğlu, Fatih Oltulu |
|---|---|
| Přispěvatelé: | Ege Üniversitesi |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Nitric Oxide Synthase Type III Nitric Oxide Synthase Type II 030204 cardiovascular system & hematology Pharmacology medicine.disease_cause Losartan Article NF-κB Diabetes Mellitus Experimental Diabetic nephropathy Diabetes Complications 03 medical and health sciences 0302 clinical medicine Enos Diabetes mellitus Medicine Animals Rats Wistar Antihypertensive Agents Cerrahi 0303 health sciences TUNEL assay biology 030306 microbiology business.industry Liver Diseases Therapeutic effect NF-kappa B General Medicine Streptozotocin biology.organism_classification medicine.disease VEGF Rats angiotensin II receptor blocker iNOS eNOS business Oxidative stress medicine.drug Hepatic damage |
| Zdroj: | Turkish Journal of Medical Sciences |
| Popis: | Background/aim Losartan, an antihypertensive drug, is highly preferred in patients with diabetes mellitus (DM) and hypertension because of its retarding effect on diabetic nephropathy. In this study, we investigated the potential therapeutic effect of different doses of losartan on hepatic damage in a streptozotocin (STZ, 50 mg/kg)-induced DM model in rats. Materials and methods In this study, five different groups were formed: control, DM, low-dose losartan (5 mg/kg), mid-dose losartan (20 mg/kg), and high-dose losartan (80 mg/kg). Liver tissues of experimental groups were evaluated immunohistochemically for TUNEL, iNOS, eNOS, VEGF, and NF-κB pathways. In addition to immunohistochemical analysis, analyses of SOD and MDA, which are oxidative stress markers, were also performed and the results were evaluated together. Results When biochemical and immunohistochemical findings were evaluated together, it was found that the results obtained from the mid-dose losartan group were closer to those of the control than the other groups. Conclusion This study indicated that mid-dose losartan administration may have a therapeutic effect by inhibiting apoptosis and regulating iNOS, eNOS, VEGF, and NF-κB protein expressions in DM-induced hepatic damage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|